ATLANTA, Georgia, USA, April 28, 2026
PharmaLogic Holdings Corp., a leading contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, has announced the opening of a state-of-the-art PET radiopharmaceutical manufacturing facility in Atlanta, marking a major expansion of its U.S. production network. The new facility represents a critical investment in domestic radiopharmaceutical infrastructure, aimed at improving patient access to advanced diagnostic and therapeutic radiopharmaceuticals across the Southeast and beyond. As part of a broader $250 million strategic expansion plan, the facility strengthens PharmaLogic’s position in delivering cGMP-compliant manufacturing and distribution capabilities for both clinical and commercial-stage radiopharmaceutical products.
Expanding cGMP Radiopharmaceutical Manufacturing Capacity
The Atlanta facility is equipped with cutting-edge positron emission tomography (PET) manufacturing technology, enabling the production of highly specialized radiopharmaceuticals used in oncology, cardiology, and neurology imaging and therapy. Designed to meet stringent current Good Manufacturing Practice (cGMP) standards, the site enhances PharmaLogic’s ability to produce time-sensitive radiopharmaceutical doses with high precision and quality assurance.
Radiopharmaceuticals require rapid production and distribution due to their short half-lives, making localized manufacturing infrastructure essential for ensuring timely delivery to hospitals and imaging centers. By expanding its production capacity, PharmaLogic is addressing a critical gap in the U.S. healthcare system, where demand for advanced nuclear medicine diagnostics and therapeutics continues to grow.
Strengthening Supply Chain and Patient Access
Advertisement
Strategically located in Atlanta, the new facility serves as a regional hub for efficient distribution of radiopharmaceuticals, enabling faster and more reliable delivery to healthcare providers across the Southeast. This expansion supports PharmaLogic’s mission to improve patient access to next-generation imaging agents and targeted radiotherapies, which are increasingly important in the diagnosis and treatment of complex diseases such as cancer.
The facility also provides dedicated resources for research and development of novel radiopharmaceutical compounds, supporting innovation in precision medicine. With its growing network, PharmaLogic now delivers over 2.5 million doses annually, reflecting its масштаб and operational efficiency in the global radiopharmaceutical market.
Strategic Growth and Industry Leadership in Radiopharma
The Atlanta opening is part of PharmaLogic’s ongoing national expansion, following recent facility launches in Cincinnati, the Bronx, Salt Lake City, and Los Angeles. This coordinated growth strategy is designed to build a comprehensive, scalable radiopharmaceutical manufacturing and distribution platform, capable of supporting both clinical development programs and commercial supply chains.
As the only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries, PharmaLogic continues to demonstrate leadership in this highly specialized sector. The company’s integrated model, spanning development, manufacturing, and distribution, enables seamless support for pharmaceutical partners throughout the product lifecycle.
From a cGxP perspective, the expansion underscores the importance of robust GMP compliance, quality systems, and regulatory oversight in the production of radiopharmaceuticals, which combine the complexities of both pharmaceuticals and radioactive materials. The facility’s advanced capabilities highlight the increasing convergence of biopharma innovation and manufacturing excellence, ensuring that new therapies can be produced at scale while maintaining the highest standards of safety and efficacy.
As demand for precision diagnostics and targeted therapies continues to rise, PharmaLogic’s investment in infrastructure positions the company at the forefront of the evolving radiopharmaceutical landscape. The Atlanta facility not only enhances regional supply capabilities but also supports the broader goal of expanding global access to life-saving radiopharmaceutical treatments, reinforcing the critical role of manufacturing innovation in modern healthcare.
Source: PharmaLogic press release
